Loading
Life sciences · Journal article
Frontiers in Oncology · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Brain metastasis from cervical cancer is exceptionally rare, occurring in 0.4%–2.3% of cases and portending a dismal prognosis, with a median survival of approximately 6.2 months after the diagnosis of brain metastasis. Here we report a 51-year-old woman initially diagnosed with stage IVB papillary squamous cell carcinoma of the cervix. Initial therapy combining albumin-bound paclitaxel, cisplatin, and the anti-PD-1 antibody tislelizumab, followed by pelvic radiotherapy, achieved durable disease control. Nineteen months after diagnosis, she developed memory decline and headache; brain MRI disclosed large, radiologically presumed metastases in the right frontal-basal ganglia and left occipital lobe. As the patient declined surgery, she received bevacizumab, paclitaxel, and the bispecific PD-1/CTLA-4 antibody iparomlimab/tuvonralimab (Ipa-tuv), together with focal fractionated VMAT (3900 cGy in 13 fractions) to the brain lesions. The dominant lesion decreased from 66 × 54 × 58 mm to 45 × 54 × 49 mm, and neurological symptoms resolved. Because of financial constraints, Ipa-tuv was later discontinued and she was maintained on bevacizumab plus chemotherapy. At the last two imaging time points, an increase in perilesional edema was noted; no clear size-based progression was demonstrated, although progression, radiation-related change, and treatment-related necrosis could not be excluded. At the last radiological assessment (January 25, 2026), the overall survival was approximately 34 months from the initial diagnosis and approximately 15 months since the diagnosis of radiologically presumed brain metastases. This case describes the observed response to a multimodal treatment strategy, although the contribution of any single component cannot be determined, and further prospective trials are warranted.